I feel privileged to write this commentary as an introduction to this special issue of Neurochemical Research dedicated to Dr. Harold Steve White. In fact, I can think of no other scientist who more than Steve deserves to be honored for achievements related to advancing the pharmacological treatment of epilepsy. Steve is a true giant in this field, having worked tirelessly for almost 40 years, and continuing to work, to test potential new antiepileptic compounds and develop new models, thus leading the way in promoting novel paradigms for drug discovery.
Although I personally met Steve only in the late nineties, when the two of us were invited to speak at an international symposium in Germany, his name had been familiar to me for many years, because Dr. Harvey J. Kupferberg, who was then in charge of the Anticonvulsant Drug Screening Program at the National Institute of Health (NIH), had spoken to me very highly of a promising young scientist named Steve White. Many decades later, it is fair to say that those promises have been more than fulfilled. Over the years, I met Steve regularly at countless epilepsy meetings, we participated together in lecture tours, and we developed a strong friendship which extends to my wife, Tita, and his Kathryn. When in 2006 Dr. Kupferberg went into retirement and elected to step down from the Organizing Committee of the Eilat Conferences on New Antiepileptic Drugs (AEDs), a unique biannual event that brings together stakeholders and a sprinkling of grey hair, Steve remains the same downto-earth and approachable man I met decades ago. Indeed, everyone who meets him can testify that he is always ready to listen and help, and that his warm, humble approach to inter-personal relationships contrasts with his top-level standing as a scientist.
Despite important progress in the current pharmacological armamentarium, at least one-third of people with epilepsy fail to achieve complete seizure control with available treatments. These people rely on the work and dedication of scientists like Steve to keep alive their hope for the discovery of more effective therapies that will control their seizures, or even cure their epilepsy. In the pursuit of these goals, Steve has now taken up new challenges at the University of Washington, and we all look forward to benefiting from his future research achievements which, surely, will not take long to materialize and to impact clinical practice. models, he also strives to understand the molecular and pathophysiological mechanisms involved in both the models and the disease process. The discovery by his team of the gene responsible for the occurrence of audiogenic seizures in the Frings mouse is a typical example of this approach, whose implications for therapeutic innovation are obvious.
Steve's excellence as a researcher is accompanied by unique qualities as a communicator and teacher. On countless occasions I have listened to his lectures around the world, and yet I am learning something new every time. I also admire his ability to transmit not just knowledge, but also enthusiasm for the discipline.
In recognition of all his achievements, Steve has received many national and international prizes and awards, and most recently the Ambassador for Epilepsy Award bestowed by the International League against Epilepsy and the International Bureau for Epilepsy. Yet, in spite of all those tributes,
